Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck, Indian Government In Talks For Gardasil Supplies; Aim To Enroll 600 For Mandatory Trials

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Merck has initiated talks with the Indian health ministry to supply Gardasil vaccines for use in government health institutions. Merck has launched the human papillomavirus vaccine Gardasil in India at half its international price and intends to make the drug available to a larger population base through the government's national immunization programs (PharmAsia News, Oct. 14, 2008)

You may also be interested in...

India’s Supreme Court To Govt: Respond To Charges Of Safety Breech In Gardasil, Cervarix

In the latest of a series of court interventions, the Supreme Court has asked the regulatory agency to come clear on approvals for Gardasil and Cervarix.

Merck Launches Gardasil In India At Half U.S. Price

MUMBAI - Merck's India affiliate MSD Pharmaceuticals has launched blockbuster cervical cancer vaccine Gardasil in India at $170 (Rs 8,400) per three-dose regimen, nearly half of its U.S. price of $350

New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup

PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts